Posts Tagged by health care
|October 6, 2015||Posted by Anharris under Client Releases, Highlight 2, Innovation, Life Science, Press Releases|
Sequence data generated with NuGEN’s target enrichment technology can be processed in BaseSpace using new app to mark duplicates and perform quality trimming
San Carlos, CA -OCT. 6– NuGEN Technologies is pleased to announce that scientists and clinicians using its Ovation Target Enrichment System to prepare biologic samples for genomic analysis can now process resulting sequence data in BaseSpace–a cloud computing platform, hosted by Illumina, Inc.
“NuGEN’s new Ovation Target Enrichment System Data Processing Application will allow the large community of Illumina sequence platform users to further streamline the rapid and convenient workflow of our Ovation Target Enrichment System products,” said Alan Dance, VP of Marketing at NuGEN.
The Ovation Target Enrichment product line employs Single Primer Enrichment Technology (SPET), a novel approach for enrichment of genomic DNA targets or cDNA for RNA target regions. SPET products allow researchers and clinicians to quickly and accurately enrich biologic samples for sensitive detection of a wide range of genomic markers including mutations, SNPs, indels, gene fusions, alternately spliced transcripts and copy number variants.
The new NuGEN-application, published on BaseSpace on September 30, provides an intuitive user interface for uploading sequence data. The application performs quality trimming and probe trimming on the parsed data – removing data derived from bases with low sequencing quality scores and aligning high quality data to the UCSC human reference genome.
Subsequently, PCR duplicate reads created during the library amplification process are identified using a random N6 sequence, unique to the Ovation Target Enrichment System workflow positioned adjacent to the barcode index.
Output files from the Ovation Target Enrichment System Data Processing Application for BaseSpace include processed BAM files with PCR duplicates removed or marked, processed FASTQ files with duplicates removed, and UCSC bigWig tracks with duplicates removed for visualization using the UCSC human genome browser.
For full details, visit http://www.nugen.com/content/ovation-target-enrichment-system-data-processing-application.
NuGEN Technologies Inc. is a rapidly-growing, privately-held company providing innovative products and systems for the preparation of biologic samples for targeted genomic analysis. Founded in 2000 and based in San Carlos, CA, NuGEN has long been at the cutting edge of genomic technology, with accurate, cost-effective reagent kits for even the most challenging sample types. NuGEN products are used in more than 1000 leading life science institutes and in diagnostic and pharmaceutical companies in 40 countries.
Anita Harris, Harris Communications Group
The Harris Communications Group is an award-winning PR and marketing firm specializing in outreach for health care, life sciences and technology, worldwide.
|January 6, 2012||Posted by Anharris under Cool Companies, HarrisCom News, Health, Innovation, Life Science|
Life Science Startup to Target Multiple Disease Mechanisms
I’m pleased to report that Harris Communications Group Advisory Board Member Robert Langer of MIT is involved in yet another life science startup.
It’s a biotech company called “Blend Therapeutics” that will develop a new class of medicines possessing “unprecedented ability to precisely control each agent’s therapeutic action in concert… ” The goal is to “predictably, effectively, and safely target the multiple mechanisms underlying complex diseases, ” according to a press release.
Blend was founded by three leaders in the fields of chemistry and nanomedicine: Langer, who is David H. Koch Institute Professor at the Massachusetts Institute of Technology; Stephen J. Lippard, PhD, Arthur Amos Noyes Professor of Chemistry at MIT; and Omid Farokhzad, MD, Director of the Laboratory of Nanomedicine and Biomaterials and Associate Professor of Anesthesia, Brigham and Women’s Hospital and Harvard Medical School.
Blend has received financial backing from Flagship Ventures, New Enterprise Associates and NanoDimension.
Langer said: ” We see unparalleled opportunity to translate innovative science into important drugs for patients in need, and we’re excited by the strength of our founding investors and management who share our vision of building a successful biotechnology company that is foremost about improving the lives of patients.”
In addition to Langer, Lippard and Farokhhzad, Blend’s Scientific Advisory Board includes eight thought leaders in the fields of chemistry, cancer biology, immunology and medicine:
• Dennis Ausiello, MD, Chief of Medicine and Jackson Professor of Clinical Medicine, Massachusetts General Hospital and Harvard Medical School
• Philip Kantoff, MD, Chief Clinical Research Officer and Professor of Medicine, Dana Farber Cancer Institute and Harvard Medical School
• Alexander Klibanov, PhD, Novartis Professor of Chemistry and Bioengineering, Massachusetts Institute of Technology;
• Ulrich von Andrian, MD, PhD, Mallinckrodt Professor of Immunopathology, Harvard Medical School
• Bruce R. Zetter, PhD, Charles Nowiszerski Professor of Cancer Biology, Children’s Hospital Boston and Harvard Medical School.
MaestroTM is a trademark of Blend Therapeutics, Inc. More information is available at http://www.blendtx.com.
—Anita M. Harris
Anita Harris is the president of Harris Communications Group, a Cambridge, MA public relations firm specializing in strategic marketing communications, thought leadership and social media for companies involved in health, science, technology and energy, worldwide. She also blogs at newcambridgeobsersver.com.